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Abstract
Background: Many HIV treatment programs in resource-limited settings are plagued by high rates of loss to follow-up
(LTFU). Most studies have not distinguished between those who briefly interrupt, but return to care, and those more
chronically lost to follow-up.
Methods: We conducted a retrospective cohort study of 11,397 adults initiating antiretroviral therapy (ART) in 71 Southern
African Catholic Bishops Conference/Catholic Relief Services HIV treatment clinics between January 2004 and December
2008. We distinguished among patients with early death, within the first 7 months on ART; patients with interruptions in
laboratory monitoring (ILM), defined as missing visits in the first 7 months on ART, but returning to care by 12 months; and
those LTFU, defined as missing all follow-up visits in the first 12 months on ART. We used multilevel logistic regression
models to determine patient and clinic-level characteristics associated with these outcomes.
Results: In the first year on ART, 60% of patients remained in care, 30% missed laboratory visits, and 10% suffered early
death. Of the 3,194 patients who missed laboratory visits, 40% had ILM, resuming care by 12 months. After 12 months on
ART, patients with ILM had a 30% increase in detectable viremia compared to those who remained in care. Risk of LTFU
decreased with increasing enrollment year, and was lowest for patients who enrolled in 2008 compared to 2004 [OR 0.49,
95%CI 0.39–0.62].
Conclusions: In a large community-based cohort in South Africa, nearly 30% of patients miss follow-up visits for CD4
monitoring in the first year after starting ART. Of those, 40% have ILM but return to clinic with worse virologic outcomes
than those who remain in care. The risk of chronic LTFU decreased with enrollment year. As ART availability increases,
interruptions in care may become more common, and should be accounted for in addressing program LTFU.
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Introduction
In 2009, South Africa was home to the greatest number of
people living with HIV in the world – 5.7 million [1]. In response
to this epidemic, South Africa initiated the largest HIV treatment
program in the world, placing 1 million people on antiretroviral
therapy (ART) by the end of 2009 [1].
Despite tremendous advances in the scope and reach of HIV
care and treatment in South Africa and other resource-limited
countries, high rates of loss to follow-up (LTFU) have been
reported in systematic reviews of the literature, approaching 70%
before ART initiation and approximately 25% one to three years
after ART initiation [2,3]. Up to 50% of patients who are lost to
follow-up in some programs are later found to be dead, with many
deaths occurring in the first 6 months after ART initiation [4].
LTFU has, therefore, been increasingly recognized as an
important programmatic challenge, and has been regarded as a
measure of program effectiveness [4–6]. However, because of the
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resource-limited settings, LTFU populations from any given HIV
treatment program may unknowingly include heterogeneous
groups of patients with distinct outcomes. Such outcomes include
patient deaths, undocumented transfers of care to other sites, and
transient interruptions in care, in addition to actual loss of contact
with patients [7].
Routine patient monitoring is accepted as a cornerstone of
HIV disease management and program evaluation [8]. While the
implications of chronic LTFU and unstructured ART interrup-
tion have received substantial attention, and include increased
risk of treatment failure and death, the implications of brief
interruptions in care, which may include any combination of
non-compliance with clinical visits, laboratory assessments, or
ART are less certain [9]. Two randomized trials conducted in
resource-limited settings suggest that when compared to clinical
monitoring alone routine laboratory monitoring plays an
important role in the early recognition of treatment failure and
prevention of progression to AIDS and death [10,11]. Patients
with brief interruptions in chronic care, including laboratory
monitoring, may also be at increased risk for poor outcomes.
Definitions of LTFU, however, are not standardized across
studies with respect to time since last visit, and most studies do
not account for such patients who interrupt, but then return to
care [12].
Our objective was to study patients newly initiated on ART with
suboptimal adherence to HIV care – either with brief interrup-
tions in care or chronic LTFU – in addition to patients with early
mortality. We investigated patient and clinic level factors
associated with these patient groups, and virologic response
among those in care and those with interrupted care.
Methods
Ethics Statement
IRB approval was obtained from the Massachusetts General
Hospital and from the University of Cape Town.
Setting
The Catholic Relief Services and Southern African Catholic
Bishops Conference (CRS/SACBC) are faith-based, non-govern-
mental organizations that have been providing care to HIV-
infected individuals in South Africa since 2003. The PEPFAR-
funded HIV treatment program commenced largely in concert
with South Africa’s 2004 national ART roll-out. It was initially
launched in 20 facilities, most of which were pre-existing home-
based care programs run by the Catholic Church. The program is
now comprised of 71 sites (14 central and 57 satellite clinics),
which have provided care to over 70,000 patients since 2004 [13].
These treatment sites span 8 of the 9 South African provinces.
They are situated in rural, urban, peri-urban, squatter, as well as
mining communities, and provide services to children, adults, and
pregnant women. HIV services are provided free of charge in
hospitals, primary health clinics, primary HIV clinics, and
residential facilities. Clinics are staffed by teams typically including
at least one part-time doctor and two nurses, in addition to
counselors and adherence monitors. Treatment protocols closely
follow South African National Department of Health and World
Health Organization guidelines [14]. In addition to ART services,
all programs provide voluntary testing and counseling, while some
also provide inpatient ‘‘hospice’’ treatment, residential homes for
orphans and vulnerable children, educational programs, drug and
alcohol rehabilitation services, and other community development
initiatives.
Study Sample
The study population is comprised of adults ($15 years) who
enrolled in the CRS/SACBC treatment programs between
January 2004 and December 2008. Patients included in the
analysis were those who were eligible for ART at clinic enrollment
(baseline CD4 count ,200/uL or WHO stage III or IV disease),
subsequently initiated ART, and had at least 400 days of potential
follow-up time on ART before the end of the study. We included a
minimum follow-up time in order to have an observation period
sufficient to capture brief interruptions in care.
Data Elements
After clinic enrollment, patients received baseline clinical
assessment and CD4 count testing. Those with CD4 counts
#200/uL or WHO stage III or IV disease, were started on a
standard regimen of stavudine, lamivudine, and efavirenz (unless
contraindicated) after completing ART literacy training. Upon
ART initiation, patients received monthly adherence assessments,
3 to 6 monthly clinical follow-up, and 6 monthly laboratory follow-
up with CD4 testing, and, in some cases, HIV RNA monitoring.
Only those clinic visits associated with routine laboratory
monitoring were entered into the database and available for
analysis. An adherence counselor typically contacted patients who
defaulted from care either by phone, home-visit, or both. The
details of this practice varied by clinic. A minimum set of
demographic and clinical variables was collected at each clinic site
and entered into a standardized program database.
Definitions
A patient visit was defined as a follow-up appointment
associated with CD4 monitoring. Since first published in 2004,
South African national HIV treatment guidelines have recom-
mended 3-monthly clinical follow-up and 6-monthly CD4
monitoring [15]. Patients were categorized into one of four
mutually exclusive groups reflecting concordance with these
guidelines. Those in care were guideline-concordant. They were
alive and had at least one visit between 30 and 210 days after ART
initiation. Patients with interrupted laboratory monitoring (ILM) had no
follow-up visits between 30 and 210 days after ART initiation, but
returned to clinic for laboratory monitoring by 400 days. LTFU
was defined as having no follow-up visits between 30 and 400 days
after ART initiation. Patients with early death had a documented
death within the first 210 days after starting ART. Patient deaths
were ascertained passively. Clinics were notified of patient deaths
by home-based caregivers, family members, or by residential
facilities associated with the clinics. Patients with documented
transfers to another facility were assumed to be in care for this
analysis.
Statistical Analysis
Bivariate and multivariate, multilevel multinomial logistic
regression modeling was used to assess the relationship of
patient-level factors (age, gender, baseline CD4 count – the first
CD4 count after clinic enrollment, year of enrollment) and clinic-
level factors (urban, peri-urban, or rural, number of patients on
ART, time to ART initiation) on the odds of ILM, LTFU, and
dying within 7 months of ART initiation, compared to remaining
in care. Multilevel modeling was required to account for patient
clustering within satellite clinics, which were clustered within
primary clinics [16]. Multinomial modeling was required to
compare multiple outcomes (ILM, LTFU, early death) with the
reference group (in care) [16]. Logistic regression was favored over
time-to-event analysis to allow us to characterize patient
Interrupted Care, Early Death, and LTFU
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outcomes across patient enrollment year. Covariates with
associations at p#0.10 in any of the univariate models were
included in the final multivariate models. Four separate
Cochran-Armitage tests for trend (one for each of the outcomes
against all other outcomes combined) were conducted to assess
changes in the distribution of outcomes with patient enrollment
year [17,18]. The Bonferroni correction was used to account for
multiple comparisons, and, as a result, these tests were assessed
at the 0.05/4=0.0125 significance level [19]. A test of
proportions was used to compare the proportion of patients
with detectable viral loads (HIV RNA .400 copies/uL) at 12
months of follow-up on ART of patients in care to those with
ILM. By definition, LTFU patients did not have a follow-up visit
at 12 months, so a comparison with this group was not
performed. Data were analyzed using SAS version 9.2, SAS
Institute Inc. 2008.
Results
Cohort Description
Between 2004 and 2008, there were 22,888 ART-naive adults
enrolled in the CRS/SACBC HIV treatment programs with
advanced HIV disease (CD4 count #200/uL or WHO stage III or
IV), for whom data were available. The analysis focused on 11,397
persons who initiated ART and had at least 400 days of potential
observation time after ART initiation and before the end of the
study. Follow-up data were restricted to the first 400 days after
ART initiation for all patients. Thirty-eight percent of patients
were enrolled in urban programs, 44% in peri-urban programs,
and 18% in rural programs.
The number of ART-naı ¨ve, ART-eligible patients enrolled in
central clinics over the study period ranged from 372 at the
smallest site to 5153 at the largest. On average, 65% of ART-
eligible patients were initiated on ART.
Baseline Patient Characteristics
The majority of patients were female (67%). Median age was 35
years, and median baseline CD4 count at enrollment was 101/uL
[IQR: 43/uL,160/uL] (Table 1). CD4 count was 108/uL [IQR:
47/uL, 166/uL] among patients who interrupted laboratory
monitoring and 48/uL [IQR: 15/uL, 106/uL] among patients
who died in the first 7 months after ART initiation. The median
time from clinic enrollment to ART initiation was 34 days [IQR:
17 days, 65 days]. This duration ranged from a median of 28 days
[IQR: 14 days, 53 days] for patients with early death to 35 days
[IQR: 20 days, 70 days] for patients in care.
Patient Outcomes
At the end of the study period, 63% of patients remained
consistently in care (n=7,215), 28% (n=3,194) missed visits, and
9% (n=988) had early death. Of the patients in care, 26%
(n=1,905) had documented transfers to another facility after a
median of 399 days on ART. Of the 3,194 patients who missed
visits 1,236 (11% of cohort) had ILM, and 1,958 (17% of cohort)
were LTFU (Figure 1). Across all central clinics, the proportion of
patients classified as LTFU ranged from 1% to 35%; those with
ILM ranged from ,1% to 26%, and early deaths ranged from
,1% to 22%. Patients who interrupted laboratory monitoring had
an increase in median CD4 count from 108/uL at baseline to 257
cells/uL when monitoring was resumed. Of note, 416 patients (4%
of cohort) had late deaths, after the first 7 months on ART. These
deaths occurred a median of 436 days after ART initiation. Given
that outcomes were ascertained after 400 days of follow-up, these
patients were assigned to the outcome (in care, ILM, or LTFU)
that applied at the time of study censorship.
Table 1. Summary of baseline patient and clinic characteristics in a cohort study of LTFU in a large South African ART program.
Characteristics
Overall
(n=11,397)
In Care
(n=7,215)
Interrupted Laboratory
Monitoring (n=1,236)
LTFU
(n=1,958)
Early Death
(n=988)
Age median years [IQR] 35 [30, 42] 35 [30, 43] 35 [30, 41] 34 [29, 41] 36 [30, 43]
Sex % Female 66.5 67.8 63.9 65.6 62.3
% Male 33.5 32.2 36.1 34.4 37.7
Enrollment HIV RNA median log10 copies/mL 4.93 4.91 4.91 4.89 5.13
Enrollment CD4 count median/uL [IQR] 101 [43, 160] 107 [49,164] 108 [47, 166] 103 [44, 161] 48 [15, 106]
Enrollment Year % 2004 6.6 6.4 5.3 7.6 8.2
% 2005 19.9 19.2 19.9 19.6 25.2
% 2006 21.0 20.8 19.3 22.6 21.5
% 2007 25.8 26.3 20.6 28.6 23.2
% 2008 26.7 27.3 34.9 21.6 21.9
Geographic description % Urban 38.2 36.9 44.1 58.3 21.6
% Peri-Urban 43.7 47.1 32.2 22.5 71.1
% Rural 18.1 16.0 23.7 19.2 7.3
Number of patients on ART % #100 30.5 8.5 14.2 18.6 7.4
% 101–500 24.1 26.7 16.8 13.5 34.4
% 501–1000 11.8 25.4 25.1 14.4 33.4
% .1000 33.6 39.4 43.9 53.5 24.8
Days to ART initiation median [IQR] 34 [17, 65] 35 [20, 70] 34 [14, 64] 29 [14, 61] 28 [14, 53]
LTFU: Loss to Follow Up, ART: Antiretroviral Therapy, IQR; Interquartile Range.
doi:10.1371/journal.pone.0032993.t001
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The number of patients that initiated ART in the CRS/SACBC
clinics increased with each calendar year, from 753 in 2004 to
3,042 in 2008 (Figure 2). Over this period, the proportion of
patients who remained in care increased from 61% in 2004 to
65% in 2008 (p-value for Cochran-Armitage test for
trend=0.0190; not significant at the 0.0125 level). There was
also an overall increase in the proportion of patients who had
ILM, from 9% to 14% (p-value=0.1128), and significant
decreases in both LTFU, from 20% to 14% (p-value=0.0016),
and in early deaths, from 11% to 7% (p-value=,0.0001)
(Figure 2). During the same time, there was a small decline in
the proportion of patients presenting to clinic with advanced
disease. In 2004, 54% of patients presented with a baseline CD4
count #100/uL, compared to 49% in 2008.
In multivariate analysis, later year of enrollment was associated
with decreased risk of LTFU. Compared to patients enrolled in
2004, patients enrolled in 2008 had a 51% reduction in the risk of
LTFU [OR 0.49; 95%CI 0.39–0.62]. We did not find similar
trends related to ILM or early death.
Detectable Viral Load at 12 Months
Of all patients who remained in care, 71% had a viral load
obtained a median of 376 days after ART initiation; 13% had
Figure 1. Summary of patient outcomes in a cohort study of LTFU in a large South African ART program.
doi:10.1371/journal.pone.0032993.g001
Figure 2. Trends in LTFU and program size in the Catholic Relief Services/Southern African Catholic Bishops Conference HIV
treatment program, 2004–2008.
doi:10.1371/journal.pone.0032993.g002
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with ILM, 64% had a viral load obtained a median of 393 days
after ART initiation; 17% had detectable viral loads. There was a
30% increase in detectable viremia at 12 months among patients
with ILM compared to patients in care (p=0.0112).
Factors Associated with Interruped Laboratory
Monitoring, LTFU, or Death
In multivariate analysis, female sex was associated with a
decreased odds of ILM [OR 0.80; 95%CI 0.70–0.92], LTFU [OR
0.82; 95%CI 0.73–0.91], and early death [OR 0.86; 95%CI 0.75–
0.99] compared to male sex. Aside from female sex, we did not
find any other patient-level factors associated with ILM (Table 2).
Baseline CD4 count was a predictor of early death, but not
LTFU. In univariate analysis, patients with baseline CD4 ,50/uL
had an increased risk of LTFU [OR 1.3; 95%CI 1.06–1.61]
compared to those with baseline CD4 .200/uL, but this
relationship did not persist in the multivariate model [OR 1.21;
95%CI 0.99–1.49]. In multivariate analysis, the risk of early death
increased with decreasing baseline CD4 count [OR 6.43; 95%CI
4.13–9.99], for patients with baseline CD4 ,50/uL compared to
those with baseline CD4 .200/uL.
Among all factors assessed, we did not find any clinic
characteristics associated with higher rates of LTFU. Longer time
to ART initiation was associated with a decreased risk of early
death [OR 0.78; 95%CI 0.67–0.90], and there was a trend
suggesting decreased risk of ILM among patients attending larger
programs (.100 patients on ART), (Table 2).
When patients with late deaths (after 7 months on ART) were
analyzed in a separate multinomial, multivariate model comparing
ILM, LTFU, early death, and late death with the reference group
(in care), we saw no change in the factors associated with ILM,
LTFU, and early death. Enrollment year after 2005 was associated
with a decreased odds of late death; patients enrolled in 2006,
2007, and 2008 had a 49% [95%CI 28–64], 70% [95%CI 57–79],
and 76% [95%CI 65–83] reduction in the odds of late death
compared to those in care. Additionally, patients with a baseline
CD4 count #100/uL had an increased risk of late death with OR
1.66 [95%CI 1.09–2.54] for patients with baseline CD4 50–100/
uL, and OR 1.75 [95%CI 1.14–2.62] for patients with baseline
CD4 count ,50/uL.
Discussion
In an analysis of over 11,000 patients newly-initiated on ART
between 2004 and 2008 across South Africa, 63% of patients
remained stably in care in the first year after ART initiation. Nine
percent of patients suffered early death within the first seven
months after ART initiation. These patients presented with very
advanced disease, with a median CD4 count of 48/uL. Missed
Table 2. Factors associated with interrupted laboratory monitoring, LTFU, and early death in multivariate analysis*.
Interrupted laboratory monitoring LTFU Early Death
OR p OR p OR p
Age (years) .35 1.00 1.00 1.00
#35 1.03 [0.91–1.17] 0.6356 1.07 [0.97–1.19] 0.1940 1.01 [0.88–1.17] 0.8507
Sex Male 1.00 1.00 1.00
Female 0.80 [0.70–0.92] 0.0012 0.82 [0.73–0.91] 0.0003 0.86 [0.75–0.99] 0.0453
Enrollment CD4
(cells/uL)
.200 1.00 1.00 1.00
101–200 0.93 [0.74–1.17] 0.5065 1.01 [0.83–1.23] 0.9009 2.16 [1.38–3.38] 0.0007
50–100 0.84 [0.66–1.08] 0.1748 1.03 [0.83–1.27] 0.8060 3.64 [2.32–5.72] ,0.0001
,50 1.00 [0.79–1.27] 0.9886 1.21 [0.99–1.49] 0.0698 6.43 [4.13–9.99] ,0.0001
Enrollment Year 2004 1.00 1.00 1.00
2005 1.21 [0.90–1.63] 0.1989 0.96 [0.77–1.19] 0.6963 1.07 [0.79–1.45] 0.6609
2006 0.90 [0.66–1.21] 0.4689 0.80 [0.64–0.99] 0.0468 1.00 [0.73–1.36] 0.9816
2007 0.76 [0.56–1.02] 0.0681 0.66 [0.53–0.83] 0.0003 1.02 [0.75–1.39] 0.8801
2008 1.25 [0.93–1.67] 0.1362 0.49 [0.39–0.62] ,0.0001 0.90 [0.66–1.22] 0.4962
Geographic
Description
Urban 1.00 1.00 1.00
Peri-Urban 0.69 [0.28–1.70] 0.4187 0.25 [0.10–0.59] 0.0017 1.71 [0.59–4.90] 0.3210
Rural 1.23 [0.40–3.77] 0.7153 0.45 [0.17–1.19] 0.1056 0.71 [0.20–2.57] 0.6014
Number of
Patients on ART
#100 1.00 1.00 1.00
101–500 0.63 [0.42–0.93] 0.0191 0.53 [0.29–0.97] 0.0396 0.72 [0.35–1.50] 0.3866
501–1000 0.82 [0.43–1.56] 0.5415 0.58 [0.23–1.48] 0.2533 1.53 [0.55–4.29] 0.4200
.1000 0.52 [0.32–0.85] 0.0083 0.74 [0.31–1.74] 0.4839 1.28 [0.51–3.24] 0.5980
Days to ART Initiation 0–30 1.00 1.00 1.00
.30 0.90 [0.79–1.03] 0.1247 0.92 [0.83–1.03] 0.1294 0.78 [0.67–0.90] 0.0006
LTFU: Loss to Follow Up, ART: Antiretroviral Therapy, OR: Odds Ratio,
*all models adjusted for all variables listed in table.
doi:10.1371/journal.pone.0032993.t002
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ILM but returned to care by 400 days, and there was a trend
towards increase over time. Importantly, patients with ILM would
often have been categorized as LTFU if the analysis did not
account for those who resumed laboratory monitoring after an
initial absence from care, and would have increased the ‘‘LTFU’’
rate in this analysis from 17% to 28%. In addition, the majority of
patients with interruptions had an increase in CD4 count and had
suppressed HIV viral load upon return to care, suggesting that
they had continued ART during the period of interrupted
monitoring. Despite this, patients with ILM had a lower rate of
virologic suppression at 12 months (83%) compared to patients
who remained in care (87%). Seventeen percent of patients were
lost to follow up at one year, but the odds of LTFU decreased
significantly with more recent enrollment year. As in several other
studies, women had a decreased risk of LTFU, ILM and death
[20,21]. While low baseline CD4 count predicted early death, we
did not identify any other baseline patient-level factors that would
distinguish patients with ILM from those ultimately lost to follow-
up.
With the critical goal of retaining patients in HIV care over
time, LTFU has been recognized as an important programmatic
metric. Patient tracing studies confirm that many patients
identified as lost to follow up have died (7%–40%), transferred
care (30%), or voluntarily withdrawn from care [6,22–24]. Each of
these types of patients has different outcomes, challenging the
notion that all LTFU reflects a poor outcome. In the current study,
which excluded known early deaths and patients with ILM, we did
not find low baseline CD4 count to be associated with higher rates
of LTFU. The same has been seen in other studies that exclude
known deaths, particularly early deaths, from the definition of
LTFU [25,26].
Despite a growing body of literature on LTFU in HIV
treatment programs, patients that interrupt, but subsequently
return to care, have received relatively little attention. While
failure to attend clinic appointments is common in the
management of chronic illness, there are few data about patients
with ILM in resource-limited settings [27–29]. In the current
study, of all patients who missed visits in the first 7 months on
ART, nearly 40% returned to clinic for monitoring and care by
one year. Another South African study found that of the one-third
of patients who defaulted from care, another one-third resumed
ART after a median of 228 days [21]. In that study, patients lost
the immunologic benefit of ART, with CD4 counts at return
comparable to the pre-ART CD4 counts [21]. In contrast, most
patients in our cohort with ILM had an increase in CD4 count and
decrease in HIV RNA upon resumption of care, suggesting that
the vast majority remained on ART. Despite this increase in CD4,
patients with ILM had lower rates of virologic suppression at 12
months compared to those who remained in care. These findings
underscore the importance of compliance with a package of care
services that include clinical and laboratory assessment. Indeed,
two randomized controlled trials with 3 to 5 years of patient
follow-up found that routine laboratory monitoring (with CD4 and
or viral load testing) was associated with improved health and
survival when compared to clinical monitoring alone in resource-
limited settings [10,11]. The authors of the DART study, which
compared laboratory monitoring to clinically driven monitoring in
Zimbabwe, reported that 59 patients would need to be monitored
for 1 year to avoid one new WHO stage 4 event or death [11].
It is possible that patients with ILM sought care or obtained
ART from other facilities. This phenomenon may be especially
relevant for highly mobile populations and in communities where
expansion in HIV treatment facilities provides patients with the
option to choose clinics that best meet their needs. It is also
possible that some patients came to clinic visits only, but did not
complete laboratory follow-up, or that incomplete record-keeping
led some patients to be misclassified, despite complying with
routine laboratory monitoring. One study from South Africa
found that among patients classified as lost to follow-up in an HIV
treatment program, 21% were still in care – half were incorrectly
identified as lost, and the other half had interrupted care but
returned [24]. These findings underscore the prevalence of missed
visits in HIV programs in resource-limited settings, as well as the
importance of data quality on the assessment of patient outcomes.
While many studies have investigated the association between
patient characteristics and LTFU, fewer have measured the
association between program characteristics and this risk. One
large meta-analysis of 33 patient cohorts in 13 Sub-Saharan
African countries found no association between cohort size or year
of program initiation and LTFU. But the ART-LINC study of 23
treatment programs in low and middle-income countries found
that larger programs had higher rates of LTFU and were less likely
to trace patients who were lost [30]. In the current study, only
patient-level factors predicted LTFU. We did not find a
relationship between program size, geographic description, or
time to ART initiation and LTFU.
Definitions of LTFU may also affect the assessment of temporal
trends of important patient outcomes. Our analysis showed a
decrease in LTFU and patient deaths, but an increase in ILM,
during the period of study. This contrasts with a study from the
IeDEA-SA cohort, which similarly showed a decline in patient
mortality, but an increase in LTFU, from 1% to 13%, between
2002 and 2007 [21]. In this study of eight public sector programs,
the authors suggested that rapid program growth over this period,
and subsequent strain on monitoring systems, might explain the
increase in LTFU [21]. While we also found an increase in
enrollment by nearly 300% from 2004 to 2008, there are several
potential reasons for these conflicting results. First, we excluded
ILM from our definition of LTFU. Increases in ILM over time
may contribute to increasing rates of ‘‘LTFU,’’ if these patients are
included in the definition of LTFU. Second, over the course of our
study period, the CRS/SACBC programs witnessed substantial
improvements in their patient record system and developed a
more intensive home-based care program better equipped to
identify early patient defaulters, complete home visits, and
encourage patients to return to care. In fact, the home-based
care networks in many of these communities preceded HIV
treatment services, and the longstanding relationships between the
church and surrounding communities may foster different
dynamics than those seen in public sector programs.
This study has several limitations. First, we did not have
systematic ascertainment of patient outcomes, including transfers,
LTFU, and death. While all programs in the cohort had some
mechanism for tracing patients lost from care, including
notification by home-based caregivers (informal patient-trackers),
family members, and residential facilities associated with clinics, it
was not standardized across all sites. This may have introduced
ascertainment bias, and furthermore, the deaths in the LTFU
group are a minimum estimate. Second, detailed information on
ART retrieval, and clinic visits that occurred outside of laboratory
follow-up were not recorded in the clinical database. Consequent-
ly, determinations of LTFU and ILM were based solely upon
clinic visits that were tied to laboratory visits, which may have
introduced misclassification bias. We were reassured that the
predictors of early death (low baseline CD4 count and male sex)
and LTFU (male sex) were consistent with those reported in other
studies of patient retention and attrition. Finally, use of logistic
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calculate incidence of LTFU. Despite these limitations, this study
provides a novel assessment of patients lost from HIV care in a
large, multi-site, NGO-based clinical program in South Africa,
with a focus on the importance of interrupted monitoring and
care.
In summary, in the first year of ART initiation in a large multi-
site cohort in South Africa, we found that 60% of patients remain
in care, 30% miss visits, and 10% die early from advanced
immune suppression. Of the patients who miss visits, nearly 40%
have interruptions at their primary clinical sites. While most
returned to care with virologic suppression in the short term, our
study suggests that patients who interrupt care generally, and
laboratory monitoring specifically, may have worse virologic
outcomes than patients who remain in care. ILM may become
more common as ART programs become more widely available,
and studies that do not account for such interruptions will
overestimate LTFU rates. In the current study, LTFU rates
decreased from 2004–2008, while ILM increased. For program
evaluation and quality improvement, it is critical to distinguish
between these two important outcomes, and specifically to account
for patients who are successfully receiving ART in new locations.
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